focus -WSS

focus

author：knowledge 2025-09-03 14:42:25 - browse：8

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

WSS

My daughter's legacy lives on through her writing, phage therapy

'Essentially witchcraft:' A former naturopath takes on the field

UnitedHealth, Optum discontinue NaviHealth name

Readers discuss the intersection of pregnancy and addiction

Roivant's CEO is a star, but biotech's black hole persists

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Medical records are filled with copy

Coercive sterilizations revealed by STAT prompt outrage

The cancer drug shortage isn’t new — and neither are the solutions

Readers discuss the intersection of pregnancy and addiction

DIEP, the 'gold standard' of breast reconstruction, is under threat

Report captures long Covid’s disabling effects and policy challenges

Continuity nursing helped my family in our darkest PICU moments

How AI can help patients find reliable information about doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Summit: Ending the crisis of Black deaths in the U.S.

Wikipedia

Readout LOUD podcast: Live from the 2023 STAT Summit

Stephen Quake on the Chan Zuckerberg quest to conquer disease

My daughter's legacy lives on through her writing, phage therapy

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Readout: Friday, Oct. 20 biotech updates

hotspot

entertainment

focus

explore